PDF(Pubmed)
Abstract：
Dry eye disease (DED) incidence is continuously growing, positioning it to become an emergent health issue over the next few years. Several topical treatments are commonly used to treat DED; however, reports indicate that only a minor proportion of drug bioavailability is achieved by the majority of eye drops available on the market. In this context, enhancing drug ability to overcome ocular barriers and prolonging its residence time on the ocular surface represent a new challenge in the field of ocular carrier systems. Therefore, research has focused on the development of multi-functional nanosystems, such as nanoemulsions, liposomes, dendrimers, hydrogels, and other nanosized carriers. These systems are designed to improve topical drug bioavailability and efficacy and, at the same time, require fewer daily administrations, with potentially reduced side effects. This review summarizes the different nanotechnologies developed, their role in DED, and the nanotechnology-based eyedrops currently approved for DED treatment.
摘要：
干眼症(DED)的发病率不断增长,将其定位为未来几年内的紧急健康问题。几种局部治疗通常用于治疗DED;然而，报告表明，市场上的大多数滴眼剂只能获得很小比例的药物生物利用度。在这种情况下，增强药物克服眼屏障的能力和延长其在眼表的停留时间代表了眼载体系统领域的新挑战。因此,研究集中在多功能纳米系统的开发上，如纳米乳液，脂质体，树枝状聚合物,水凝胶,和其他纳米级载体。这些系统旨在提高局部药物的生物利用度和功效，同时,需要更少的日常管理，具有潜在的减少的副作用。这篇综述总结了开发的不同纳米技术，他们在DED中的角色，以及目前批准用于DED治疗的基于纳米技术的滴眼液。
